SurModics, Inc.  

(Public, NASDAQ:SRDX)   Watch this stock  
Find more results for SRDX
20.74
+0.05 (0.24%)
Real-time:   1:01PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 20.59 - 21.01
52 week 18.00 - 25.99
Open 20.59
Vol / Avg. 9,203.00/53,988.00
Mkt cap 281.45M
P/E 21.58
Div/yield     -
EPS 0.96
Shares 13.60M
Beta 1.21
Inst. own 87%
Sep 9, 2014
SurModics, Inc. at CL King & Associates Inc Best Ideas Conference - Webcast
Sep 3, 2014
SurModics Inc at Barrington Research Fall Investment Conference
Aug 6, 2014
SurModics Inc at CFA Society of Minnesota's InvestMNt Conference
Jul 31, 2014
Q3 2014 SurModics Inc Earnings Call - Webcast
Jul 31, 2014
Q3 2014 SurModics, Inc. Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin 25.14% 25.97%
Operating margin 36.49% 33.25%
EBITD margin - 39.52%
Return on average assets 15.01% 14.14%
Return on average equity 15.91% 15.44%
Employees 114 -
CDP Score - -

Address

9924 W 74th St
EDEN PRAIRIE, MN 55344-3523
United States - Map
+1-612-8292700 (Phone)
+1-952-5007001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

SurModics, Inc. (SurModics) is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. The Company operates in two reportable segments: the Medical Device unit, which is comprised of surface modification coating technologies to improve access, deliverability, and predictable deployment of medical devices, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device and the In Vitro Diagnostics unit, which consists of component products and technologies for diagnostic immunoassay and molecular tests and biomedical research applications. As of September 30, 2013, the Company had over 100 licensed product classes (customer products utilizing SurModics technology) already on the market generating royalties and greater than 100 customer product classes incorporating its technology in various stages of pre-commercialization.

Officers and directors

Scott R. Ward Independent Chairman of the Board
Age: 54
Bio & Compensation  - Reuters
Gary R. Maharaj President, Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Andrew D. C. LaFrence Chief Financial Officer, Vice President
Age: 50
Bio & Compensation  - Reuters
Bryan K. Phillips Senior Vice President - Legal and Human Resources, General Counsel & Secretary
Age: 42
Bio & Compensation  - Reuters
Charles W. Olson Senior Vice President & General Manager - Medical Device
Age: 49
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Joseph J. Stich Vice President, General Manager - In Vitro Diagnostics
Age: 48
Bio & Compensation  - Reuters
Timothy J. Arens Vice President - Corporate Development and Strategy
Age: 46
Bio & Compensation  - Reuters
Jose H. Bedoya Independent Director
Age: 57
Bio & Compensation  - Reuters
John W. Benson Independent Director
Age: 69
Bio & Compensation  - Reuters
David R. Dantzker Independent Director
Bio & Compensation  - Reuters